Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MBX Biosciences, Inc. (MBX – Research Report), REPRO-MED Systems (KRMD – Research Report) and Xenon (XENE – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MBX Biosciences, Inc. (MBX)
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on MBX Biosciences, Inc., with a price target of $57.00. The company’s shares closed last Monday at $29.15.
According to TipRanks.com, Ear is a 2-star analyst with an average return of
Currently, the analyst consensus on MBX Biosciences, Inc. is a Strong Buy with an average price target of $64.20, implying an 113.4% upside from current levels. In a report issued on February 24, UBS also reiterated a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
REPRO-MED Systems (KRMD)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on REPRO-MED Systems. The company’s shares closed last Monday at $4.53.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for REPRO-MED Systems with a $6.33 average price target, a 41.9% upside from current levels. In a report released today, Lake Street also reiterated a Buy rating on the stock with a $8.00 price target.
Xenon (XENE)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Xenon, with a price target of $53.00. The company’s shares closed last Monday at $60.47.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $55.92, which is a -7.7% downside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
